LabReflex
Making diagnostics clearer, smarter, and more effective. Bringing the story behind the numbers.
Latest Episodes
Power Shifts: AI, Joint Ventures & the New Healthcare Order
January 12, 2026
Episode Overview In this episode of LabReflex, Dr. Chris Zahner covers several key developments shaping clinical laboratories and healthcare in early 2026. The discussion begins with a brief update on the status of the RESULTS Act and what laboratory leaders should be watching next. From there, the episode explores the launch of ChatGPT Health and what expanding use of generative AI could mean for healthcare decision-making. The conversation then turns to recent diagnostic joint ventures and partnerships, before closing with a set of quick housekeeping updates and notable industry headlines. Segment 1: RESULTS Act — Where Things Stand The episode opens with a concise update on the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Chris reviews where the legislation currently stands in Congress, why timing matters heading into 2026, and how laboratories should be thinking about reimbursement planning while the bill remains unresolved. Rather than revisiting the full history of PAMA, the focus is on near-term implications and financial preparedness. Key points discussed include the current protection of Medicare laboratory payment rates, the possibility of future reductions under existing law, and the importance of conservative financial planning while legislative outcomes remain uncertain. Segment 2: ChatGPT Health and AI in Healthcare Chris then discusses the launch of ChatGPT Health from OpenAI and places it in the broader context of artificial intelligence in healthcare. The conversation examines what differentiates a health-focused AI deployment from general consumer tools, how patients are already using AI to interpret symptoms and lab results, and why this trend matters for clinicians and laboratories. The focus is not on technical details, but on how AI is increasingly influencing healthcare decisions upstream of testing and care delivery, shaping patient expectations and clinical workflows. Segment 3: Joint Ventures and Diagnostic Partnerships The episode next turns to recent joint ventures and partnerships in diagnostics, including health system collaborations with large laboratory organizations such as Quest Diagnostics. Chris explains why these arrangements differ from traditional outsourcing and what they signal about how health systems are thinking about laboratory operations, scale, and long-term cost management. The discussion highlights how shared-ownership models can affect governance, operational control, and the future role of hospital-based laboratories within larger networks. Segment 4: Housekeeping and Industry Updates The episode concludes with several brief updates on recent hospital closures, service line changes, and other operational developments affecting healthcare systems. Chris discusses why these events matter for laboratory access, specimen flow, and diagnostic continuity, particularly in smaller or rural communities.
Listen Now →
Year in review
December 22, 2025
LabReflex 2025 Year in Review Practical progress in an uncertain year As 2025 comes to a close, LabReflex takes a step back to reflect on what actually shaped clinical laboratories this year. This episode is not about big promises or dramatic breakthroughs. It is about how labs responded in practical ways to persistent pressure. Rather than solving long standing problems, many organizations focused on setting reasonable goals, stabilizing operations, and making incremental improvements where they could. In many ways, that mindset defined the year. Workforce strain as a permanent condition Staffing challenges did not resolve in 2025. Instead, they became part of the baseline. Labs shifted from short term crisis management to long term mitigation, prioritizing cross training, service triage, and sustainability. The conversation moved away from restoring ideal staffing levels and toward maintaining safe and reliable operations with fewer people. A more grounded view of artificial intelligence The AI conversation matured this year. Expectations collided with operational reality. While interest remained high, adoption slowed as labs focused on validation, integration, and return on effort. Where workflows were already well defined, AI showed promise. Where systems were fragmented, it added complexity rather than relief. Financial uncertainty continues to shape behavior Even without immediate reimbursement cuts, unresolved policy questions continued to influence planning and budgets. Many laboratories responded conservatively, delaying investments, tightening utilization, and modeling multiple future scenarios. The uncertainty itself became a driver of decision making. Workflow matters more than hardware A clear lesson from 2025 was that new analyzers do not fix broken systems. Attention increasingly shifted upstream to specimen flow, staffing models, ordering practices, and communication. Measuring turnaround time by phase rather than as a single number helped labs identify where meaningful improvements were actually possible. Growth areas bring new operational demands Molecular diagnostics and pharmacogenomics continued to expand, but with that growth came increased interpretive workload, reporting complexity, and infrastructure requirements. The technical barriers may be lower than they once were, but the operational burden is very real. Public health pressure returns quietly Outbreak response and policy changes reintroduced a level of background pressure that many labs had hoped was behind them. Readiness is no longer episodic. It is an ongoing expectation layered onto already constrained systems. Looking ahead to 2026 The outlook for 2026 is shaped directly by what we saw in 2025. Workforce shortages are unlikely to resolve quickly. Financial pressure remains unsettled. AI will only succeed where workflows are sound. Progress will continue, but it will be measured, deliberate, and practical. This episode is a realistic assessment of where laboratories are today and how they are moving forward. Not with sweeping transformations, but with thoughtful decisions and achievable goals.
Listen Now →
CAP Changes and New Innovations
December 15, 2025
LabReflex Podcast – Episode Notes Episode Title: Modern Lab Transitions: CAP’s 2025 Overhaul, Reliable AI, and Diagnostics on the Front Line Host: Dr. Chris Zahner and Dr. Aakash Episode Summary This episode examines the major shifts coming to clinical laboratories as CAP releases its most consequential checklist updates in years. Digital pathology, remote review, and self-collected specimens are now positioned as core operational elements rather than edge capabilities, and we break down what laboratories must understand before their next inspection cycle. We then explore a new AI methodology from Johns Hopkins, known as MIGHT, which aims to provide honest, statistically sound performance estimates for diagnostic machine-learning models—a key step toward trustworthy AI in clinical care. Additional discussion highlights emerging diagnostic technologies featured in recent CAP Today coverage, including expanded pharmacogenomics services, next-generation rapid HbA1c testing, and new frontline infectious disease platforms. We close with updates on PAMA policy movement and recent infectious disease alerts, including a rare donor-derived rabies transmission and early-season respiratory activity. Segment 1: CAP’s 2025 Checklist Overhaul Key discussion points: Digital pathology, remote data assessment, and whole slide imaging are now explicitly included under Laboratory General, signaling CAP’s expectation that digital workflows be treated as part of standard laboratory operations. Requirements related to remote review emphasize secure authentication, data encryption, and auditability. CAP has introduced a new Phase II requirement addressing self-collected specimens such as HPV kits, saliva PCR, FIT kits, and dried blood spots. Patient safety appears as a unifying theme across checklists, reinforcing expectations for labeling accuracy, cross-site consistency, and proactive risk assessments. CAP Today highlights LIS interoperability as a growing pain point for laboratories implementing digital pathology and integrated QC systems. Segment 2: Hopkins MIGHT Method for Reliable Diagnostic AI Key discussion points: MIGHT (Multidimensional Informed Generalized Hypothesis Testing) provides statistically valid estimates of sensitivity, specificity, and ROC performance for machine-learning models, even in high-dimensional, low-sample-size clinical datasets. Hopkins researchers evaluated MIGHT on 1,000 patient blood samples (352 cancer, 648 non-cancer), producing approximately 72 percent sensitivity and 98 percent specificity, and comparing 44 feature sets, with aneuploidy-based markers emerging as the strongest predictors. The method focuses on performance stability: using repeated, independent train-test splits, confidence interval calculations, and formal hypothesis testing to prevent overfitting and inflated performance claims. This approach aligns with emerging expectations from CAP for transparent, reproducible AI validation. Segment 3: Innovation Spotlight Key discussion points: Quest’s expanded pharmacogenomic testing service marks a significant shift as PGx becomes more integrated into routine primary care and specialty workflows. Approximately 30 to 40 percent of patients carry clinically actionable PGx variants, supporting broader use. Tosoh’s GR01 HbA1c analyzer received 510(k) clearance and delivers an HPLC-based A1c result in roughly 50 seconds with coefficient of variation ≤1.1 percent and detection of common hemoglobin variants, enabling near-real-time diabetes management. CAP Today also highlights two emerging diagnostic platforms: Qiagen’s QIAstat-Dx Rise, a high-throughput syndromic PCR system capable of 160 tests per day with automated priority handling, and QuickVue Flu + SARS, a CLIA-waived 10-minute antigen test designed for decentralized settings. MeMed BV, an FDA-cleared host-response assay, continues to gain traction for distinguishing bacterial from viral infections in emergency and urgent care environments. Segment 4: PAMA Update Key discussion points: Quest and LabCorp have launched a coordinated lobbying effort for a delay to the 2026 PAMA repricing cycle, joined by rural and independent laboratory groups emphasizing patient access concerns. Congressional staff have indicated openness to a potential delay, though no formal legislation has yet been introduced. If unchanged, PAMA cuts could lower reimbursement for hundreds of high-volume tests by up to 15 percent. Segment 5: Clinical Alerts Key discussion points: CDC’s MMWR describes a donor-derived rabies transmission involving a kidney recovered from a donor in Idaho who had a skunk scratch approximately six weeks prior to death. The kidney recipient, transplanted in Ohio and residing in Michigan, developed rabies about five weeks post-transplant and died. Three corneal graft recipients received post-exposure prophylaxis following graft removal and remained asymptomatic. This was the fourth known donor-derived rabies transmission in the United States since 1978. Early-season respiratory trends show high influenza-like illness activity in Colorado, Louisiana, and New York City, with rising influenza-associated hospitalizations and a doubling of norovirus positivity rates over recent months. Zika activity remains low in the United States, with only a small number of travel-associated cases reported; WHO has elevated travel risk levels in parts of Latin America and the Caribbean, and CDC has narrowed testing guidance for asymptomatic pregnant patients. Key Takeaways CAP’s 2025 checklist updates signal a structural shift toward digital workflows, remote operations, and decentralized specimen collection as standard laboratory practice. Reliable AI in diagnostics requires not just model accuracy but statistically valid and reproducible performance estimates; MIGHT represents a meaningful step in that direction. Diagnostic innovations are converging toward faster turnaround, decentralization, and clinical decision support. PAMA remains a fluid policy environment, but early signs point to potential congressional engagement on delaying reimbursement cuts. Unusual infectious events such as donor-derived rabies underscore the importance of robust donor screening and public health coordination, while respiratory trends suggest increasing demand for rapid diagnostics.
Listen Now →About LabReflex
Diagnostics sit underneath almost every decision in medicine, but most people only see the numbers and not the story behind them. LabReflex brings that story forward, giving it context, and helping people understand what matters and what does not.
Direct, practical, and grounded in actual work rather than theory. Join Dr. Christopher Zahner, a clinical pathologist and former NASA engineer, as he explores the intersection of precision, systems thinking, and diagnostic medicine.
Meet the Creator